Modeling human carcinomas: Physiologically relevant 3D models to improve anti-cancer drug development

Advanced Drug Delivery Reviews

Volumn 79, Issue , 2014, Pages 50-67

  Unger, Christine ^a   Kramer, Nina ^a   Walzl, Angelika ^a   Scherzer, Martin ^a   Hengstschläger, Markus ^a   Dolznig, Helmut ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

3D cultures; Human cancer models; Microenvironment; Organoid models; Patient derived xenograft; Spheroid; Tumor slices; Tumor stroma

Indexed keywords

DISEASES; PHYSIOLOGICAL MODELS; TUMORS;

3-D CULTURES; HUMAN CANCER; MICROENVIRONMENTS; PATIENT DERIVED XENOGRAFT; SPHEROID; TUMOR-STROMA;

PREDICTIVE ANALYTICS;

ALGINIC ACID; CISPLATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYCAPROLACTONE; SCATTER FACTOR; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BIOPRINTING; BIORESORBABLE SCAFFOLD; CANCER CELL CULTURE; CANCER CELL LINE; CANCER MODEL; CANCER MORTALITY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL ENCAPSULATION; CELL ISOLATION; CELL MIGRATION; CELL SELECTION; CELL STRUCTURE; COCULTURE; CULTURE MEDIUM; CYTOPLASM; DRUG RESPONSE; DRUG SCREENING; EXPLANT; FLOW CYTOMETRY; HUMAN; HYDROGEL; IMAGE RECONSTRUCTION; IN VITRO STUDY; IN VIVO STUDY; LAB ON A CHIP; LASER CAPTURE MICRODISSECTION; METASTASIS FREE SURVIVAL; METASTASIS POTENTIAL; MICROFLUIDICS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STROMA; THREE DIMENSIONAL CANCER CELL CULTURE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; CULTURE TECHNIQUE; DRUG DESIGN; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84919488684     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.10.015     Document Type: Review

References (245)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
3. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
4. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
5. Ocana A., Pandiella A., Siu L.L., Tannock I.F. Preclinical development of molecular-targeted agents for cancer. Nat. Rev. Clin. Oncol. 2011, 8:200-209.
6. Scannell J.W., Blanckley A., Boldon H., Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 2012, 11:191-200.
7. Ocana A., Amir E., Vera-Badillo F., Seruga B., Tannock I.F. Phase III trials of targeted anticancer therapies: redesigning the concept. Clin. Cancer Res. 2013, 19:4931-4940.
8. Arrowsmith J., Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat. Rev. Drug Discov. 2013, 12:569.
9. Kamb A. What's wrong with our cancer models?. Nat. Rev. Drug Discov. 2005, 4:161-165.
10. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-352.
11. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468.
12. Iyer V.R., Eisen M.B., Ross D.T., Schuler G., Moore T., Lee J.C., Trent J.M., Staudt L.M., Hudson J., Boguski M.S., Lashkari D., Shalon D., Botstein D., Brown P.O. The transcriptional program in the response of human fibroblasts to serum. Science 1999, 283:83-87.
13. Osborne C.K., Hobbs K., Clark G.M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985, 45:584-590.
14. Bell E., Ehrlich H.P., Buttle D.J., Nakatsuji T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 1981, 211:1052-1054.
15. Runswick S.K., O'Hare M.J., Jones L., Streuli C.H., Garrod D.R. Desmosomal adhesion regulates epithelial morphogenesis and cell positioning. Nat. Cell Biol. 2001, 3:823-830.
16. Gudjonsson T., Ronnov-Jessen L., Villadsen R., Rank F., Bissell M.J., Petersen O.W. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J. Cell Sci. 2002, 115:39-50.
17. Kunz-Schughart L.A., Heyder P., Schroeder J., Knuechel R. A heterologous 3-D coculture model of breast tumor cells and fibroblasts to study tumor-associated fibroblast differentiation. Exp. Cell Res. 2001, 266:74-86.
18. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., Mooney D.J. Engineering tumors with 3D scaffolds. Nat. Methods 2007, 4:855-860.
19. Okawa T., Michaylira C.Z., Kalabis J., Stairs D.B., Nakagawa H., Andl C.D., Johnstone C.N., Klein-Szanto A.J., El-Deiry W.S., Cukierman E., Herlyn M., Rustgi A.K. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 2007, 21:2788-2803.
20. Takagi A., Watanabe M., Ishii Y., Morita J., Hirokawa Y., Matsuzaki T., Shiraishi T. Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer Res. 2007, 27:45-53.
21. Wolf K., Wu Y.I., Liu Y., Geiger J., Tam E., Overall C., Stack M.S., Friedl P. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol. 2007, 9:893-904.
22. Pickl M., Ries C.H. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009, 28:461-468.
23. Mathis C., Poussin C., Weisensee D., Gebel S., Hengstermann A., Sewer A., Belcastro V., Xiang Y., Ansari S., Wagner S., Hoeng J., Peitsch M.C. Human bronchial epithelial cells exposed in vitro to cigarette smoke at the air-liquid interface resemble bronchial epithelium from human smokers. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013, 304:L489-L503.
24. Ronnov-Jessen L., Van Deurs B., Nielsen M., Petersen O.W. Identification, paracrine generation, and possible function of human breast carcinoma myofibroblasts in culture. In Vitro Cell. Dev. Biol. 1992, 28A:273-283.
25. Nielsen H.L., Ronnov-Jessen L., Villadsen R., Petersen O.W. Identification of EPSTI1, a novel gene induced by epithelial-stromal interaction in human breast cancer. Genomics 2002, 79:703-710.
26. Kunz-Schughart L.A., Knuechel R. Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression?. Histol. Histopathol. 2002, 17:599-621.
27. Schmeichel K.L., Bissell M.J. Modeling tissue-specific signaling and organ function in three dimensions. J. Cell Sci. 2003, 116:2377-2388.
28. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9:1392-1400.
29. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
30. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
31. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59:5002-5011.
32. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., Marshall D., Fu L., Januario T., Kallop D., Nannini-Pepe M., Kotkow K., Marsters J.C., Rubin L.L., de Sauvage F.J. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
33. Seol H.S., Kang H., Lee S.I., Kim N.E., Kim T.I., Chun S.M., Kim T.W., Yu C.S., Suh Y.A., Singh S.R., Chang S., Jang S.J. Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor. Cancer Lett. 2014, 345:56-64.
34. Chien J., Kuang R., Landen C., Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front. Oncol. 2013, 3.
35. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., Cooper Z.A., Chapman P.B., Solit D.B., Ribas A., Lo R.S., Flaherty K.T., Ogino S., Wargo J.A., Golub T.R. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
36. McMillin D.W., Negri J.M., Mitsiades C.S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 2013, 12:217-228.
37. Mullard A. 2013 in reflection. Nat. Rev. Drug Discov. 2014, 13:5-7.
38. Cook N., Jodrell D.I., Tuveson D.A. Predictive in vivo animal models and translation to clinical trials. Drug Discov. Today 2012, 17:253-260.
39. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 2010, 316:1324-1331.
40. Simone N.L., Bonner R.F., Gillespie J.W., Emmert-Buck M.R., Liotta L.A. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet. 1998, 14:272-276.
41. Rupp C., Dolznig H., Puri C., Schweifer N., Sommergruber W., Kraut N., Rettig W.J., Kerjaschki D., Garin-Chesa P. Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin. Diagn. Mol. Pathol. 2006, 15:35-42.
42. Smith M.J., Culhane A.C., Donovan M., Coffey J.C., Barry B.D., Kelly M.A., Higgins D.G., Wang J.H., Kirwan W.O., Cotter T.G., Redmond H.P. Analysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purification. Br. J. Cancer 2009, 100:1452-1464.
43. Harbeck N., Schwarze S., Schuren E., Yamamoto N., Moniwa N., Schmitt M., Dettmar P., Nathrath W., Janicke F., Hofler H., Graeff H. Model system for isolation of competent ovarian-carcinoma cells from fresh tumor-tissue by a magnetic separation technique (MACS). Int. J. Oncol. 1995, 6:1249-1254.
44. Lili L.N., Matyunina L.V., Walker L.D., Benigno B.B., McDonald J.F. Molecular profiling predicts the existence of two functionally distinct classes of ovarian cancer stroma. BioMed Res. Int. 2013, 2013:846387.
45. Richardson A.M., Woodson K., Wang Y., Rodriguez-Canales J., Erickson H.S., Tangrea M.A., Novakovic K., Gonzalez S., Velasco A., Kawasaki E.S., Emmert-Buck M.R., Chuaqui R.F., Player A. Global expression analysis of prostate cancer-associated stroma and epithelia. Diagn. Mol. Pathol. 2007, 16:189-197.
46. Rupp C., Scherzer M., Rudisch A., Unger C., Haslinger C., Schweifer N., Artaker M., Nivarthi H., Moriggl R., Hengstschlager M., Kerjaschki D., Sommergruber W., Dolznig H., Garin-Chesa P. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction. Oncogene 2014, (Epub ahead of print). 10.1038/onc.2014.18.
47. Johann D.J., Mukherjee S., Prieto D.A., Veenstra T.D., Blonder J. Profiling solid tumor heterogeneity by LCM and biological MS of fresh-frozen tissue sections. Methods Mol. Biol. 2011, 755:95-106.
48. Mukherjee S., Rodriguez-Canales J., Hanson J., Emmert-Buck M.R., Tangrea M.A., Prieto D.A., Blonder J., Johann D.J. Proteomic analysis of frozen tissue samples using laser capture microdissection. Methods Mol. Biol. 2013, 1002:71-83.
49. Espina V., Wulfkuhle J., Liotta L.A. Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment. Clin. Lab. Med. 2009, 29:1-13.
50. Jia Z., Rahmatpanah F.B., Chen X., Lernhardt W., Wang Y., Xia X.Q., Sawyers A., Sutton M., McClelland M., Mercola D. Expression changes in the stroma of prostate cancer predict subsequent relapse. PLoS One 2012, 7:e41371.
51. Shimosato Y., Kameya T., Nagai K., Hirohashi S., Koide T., Hayashi H., Nomura T. Transplantation of human tumors in nude mice. J. Natl. Cancer Inst. 1976, 56:1251-1260.
52. Staquet M.J., Byar D.P., Green S.B., Rozencweig M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat. Rep. 1983, 67:753-765.
53. Voskoglou-Nomikos T., Pater J.L., Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 2003, 9:4227-4239.
54. Fidler I.J. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev. 1991, 10:229-243.
55. de Vries J.E., Dinjens W.N., De Bruyne G.K., Verspaget H.W., van der Linden E.P., de Bruine A.P., Mareel M.M., Bosman F.T., ten Kate J. In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. Br. J. Cancer 1995, 71:271-277.
56. Jeffers M., Rong S., Vande Woude G.F. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J. Mol. Med. 1996, 74:505-513.
57. Mazzone M., Basilico C., Cavassa S., Pennacchietti S., Risio M., Naldini L., Comoglio P.M., Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest. 2004, 114:1418-1432.
58. Francone T.D., Landmann R.G., Chen C.T., Sun M.Y., Kuntz E.J., Zeng Z., Dematteo R.P., Paty P.B., Weiser M.R. Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors. Mol. Cancer Ther. 2007, 6:1460-1466.
59. Willinger T., Rongvaux A., Takizawa H., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Auerbach W., Eynon E.E., Stevens S., Manz M.G., Flavell R.A. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2390-2395.
60. Fiorillo M.T., Cabibbo A., Iacopetti P., Fattori E., Ciliberto G. Analysis of human/mouse interleukin-6 hybrid proteins: both amino and carboxy termini of human interleukin-6 are required for in vitro receptor binding. Eur. J. Immunol. 1992, 22:2609-2615.
61. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
62. Craig M., Ying C., Loberg R.D. Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. J. Cell. Biochem. 2008, 103:1-8.
63. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., Richardson A., Weinberg R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4966-4971.
64. Shultz L.D., Brehm M.A., Garcia-Martinez J.V., Greiner D.L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 2012, 12:786-798.
65. Daniel V.C., Marchionni L., Hierman J.S., Rhodes J.T., Devereux W.L., Rudin C.M., Yung R., Parmigiani G., Dorsch M., Peacock C.D., Watkins D.N. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009, 69:3364-3373.
66. Jin K., Teng L., Shen Y., He K., Xu Z., Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin. Transl. Oncol. 2010, 12:473-480.
67. Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., Arcaroli J.J., Messersmith W.A., Eckhardt S.G. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 2012, 9:338-350.
68. Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M., Hirohashi S. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 2004, 29:193-203.
69. Rubio-Viqueira B., Jimeno A., Cusatis G., Zhang X., Iacobuzio-Donahue C., Karikari C., Shi C., Danenberg K., Danenberg P.V., Kuramochi H., Tanaka K., Singh S., Salimi-Moosavi H., Bouraoud N., Amador M.L., Altiok S., Kulesza P., Yeo C., Messersmith W., Eshleman J., Hruban R.H., Maitra A., Hidalgo M. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 2006, 12:4652-4661.
70. Fichtner I., Slisow W., Gill J., Becker M., Elbe B., Hillebrand T., Bibby M. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur. J. Cancer 2004, 40:298-307.
71. Molthoff C.F., Calame J.J., Pinedo H.M., Boven E. Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int. J. Cancer 1991, 47:72-79.
72. Nemati F., Bras-Goncalves R., Fontaine J.J., de Pinieux G., De Cremoux P., Chapelier A., Daniel C., Laurent-Puig P., Livartowski A., Judde J.G., Bordier V., Poupon M.F., Decaudin D. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts. Anti-Cancer Drugs 2009, 20:932-940.
73. Chou J., Fitzgibbon M.P., Mortales C.L., Towlerton A.M., Upton M.P., Yeung R.S., McIntosh M.W., Warren E.H. Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice. PLoS One 2013, 8:e79874.
74. Julien S., Merino-Trigo A., Lacroix L., Pocard M., Goere D., Mariani P., Landron S., Bigot L., Nemati F., Dartigues P., Weiswald L.B., Lantuas D., Morgand L., Pham E., Gonin P., Dangles-Marie V., Job B., Dessen P., Bruno A., Pierre A., De The H., Soliman H., Nunes M., Lardier G., Calvet L., Demers B., Prevost G., Vrignaud P., Roman-Roman S., Duchamp O., Berthet C. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 2012, 18:5314-5328.
75. Guenot D., Guerin E., Aguillon-Romain S., Pencreach E., Schneider A., Neuville A., Chenard M.P., Duluc I., Manoir S.Du., Brigand C., Oudet P., Kedinger M., Gaub M.P. Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability. J. Pathol. 2006, 208:643-652.
76. Krumbach R., Schuler J., Hofmann M., Giesemann T., Fiebig H.H., Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur. J. Cancer 2011, 47:1231-1243.
77. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., Garrido-Laguna I., De Oliveira E., Rubio-Viqueira B., Strawn S., Wick M.J., Martell J., Sidransky D. A pilot clinical study of treatment guided by personalized tumor grafts in patients with advanced cancer. Mol. Cancer Ther. 2011, 10:1311-1316.
78. Talmadge J.E., Singh R.K., Fidler I.J., Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol. 2007, 170:793-804.
79. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., Kalyandrug S., Christian M., Arbuck S., Hollingshead M., Sausville E.A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 2001, 84:1424-1431.
80. Scholz C.C., Berger D.P., Winterhalter B.R., Henss H., Fiebig H.H. Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. Eur. J. Cancer 1990, 26:901-905.
81. Marangoni E., Vincent-Salomon A., Auger N., Degeorges A., Assayag F., de Cremoux P., de Plater L., Guyader C., De Pinieux G., Judde J.G., Rebucci M., Tran-Perennou C., Sastre-Garau X., Sigal-Zafrani B., Delattre O., Dieras V., Poupon M.F. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 2007, 13:3989-3998.
82. Fiebig H.H., Schuchhardt C., Henss H., Fiedler L., Lohr G.W. Comparison of tumor response in nude mice and in the patients. Behring Inst. Mitt. 1984, 343-352.
83. Harrap K.R., Jones M., Siracky J., Pollard L.A., Kelland L.R. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann. Oncol. 1990, 1:65-76.
84. Lock R.B., Liem N., Farnsworth M.L., Milross C.G., Xue C., Tajbakhsh M., Haber M., Norris M.D., Marshall G.M., Rice A.M. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002, 99:4100-4108.
85. Inoue K., Fujimoto S., Ogawa M. Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice. Cancer Chemother. Pharmacol. 1983, 10:182-186.
86. Boven E., Winograd B., Berger D.P., Dumont M.P., Braakhuis B.J., Fodstad O., Langdon S., Fiebig H.H. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res. 1992, 52:5940-5947.
87. Langdon S.P., Hendriks H.R., Braakhuis B.J., Pratesi G., Berger D.P., Fodstad O., Fiebig H.H., Boven E. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann. Oncol. 1994, 5:415-422.
88. Perez-Soler R., Kemp B., Wu Q.P., Mao L., Gomez J., Zeleniuch-Jacquotte A., Yee H., Lee J.S., Jagirdar J., Ling Y.H. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin. Cancer Res. 2000, 6:4932-4938.
89. Nemati F., Daniel C., Arvelo F., Legrier M.E., Froget B., Livartowski A., Assayag F., Bourgeois Y., Poupon M.F., Decaudin D. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts. Anti-Cancer Drugs 2010, 21:25-32.
90. Jimeno A., Solomon A., Karikari C., Garrido-Laguna I., Trusty D., Hruban R., Schulick R., Cameron J., Maitra A., Hidalgo M. A prospective validation of a direct tumor xenograft model in pancreatic ductal adenocarcinoma (PDA). J. Clin. Oncol. 2008, 26.
91. Fiebig H.H., Maier A., Burger A.M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 2004, 40:802-820.
92. Decaudin D. Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer. Anti-Cancer Drugs 2011, 22:827-841.
93. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
94. Singh M., Lima A., Molina R., Hamilton P., Clermont A.C., Devasthali V., Thompson J.D., Cheng J.H., Bou Reslan H., Ho C.C., Cao T.C., Lee C.V., Nannini M.A., Fuh G., Carano R.A., Koeppen H., Yu R.X., Forrest W.F., Plowman G.D., Johnson L. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 2010, 28:585-593.
95. Aspord C., Pedroza-Gonzalez A., Gallegos M., Tindle S., Burton E.C., Su D., Marches F., Banchereau J., Palucka A.K. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J. Exp. Med. 2007, 204:1037-1047.
96. Pedroza-Gonzalez A., Xu K., Wu T.C., Aspord C., Tindle S., Marches F., Gallegos M., Burton E.C., Savino D., Hori T., Tanaka Y., Zurawski S., Zurawski G., Bover L., Liu Y.J., Banchereau J., Palucka A.K. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J. Exp. Med. 2011, 208:479-490.
97. Rongvaux A., Takizawa H., Strowig T., Willinger T., Eynon E.E., Flavell R.A., Manz M.G. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu. Rev. Immunol. 2013, 31:635-674.
98. Kuperwasser C., Dessain S., Bierbaum B.E., Garnet D., Sperandio K., Gauvin G.P., Naber S.P., Weinberg R.A., Rosenblatt M. A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005, 65:6130-6138.
99. Holzapfel B.M., Thibaudeau L., Hesami P., Taubenberger A., Holzapfel N.P., Mayer-Wagner S., Power C., Clements J., Russell P., Hutmacher D.W. Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer Metastasis Rev. 2013, 32:129-145.
100. Gallico G.G., O'Connor N.E., Compton C.C., Kehinde O., Green H. Permanent coverage of large burn wounds with autologous cultured human epithelium. N. Engl. J. Med. 1984, 311:448-451.
101. Yang J., Yamato M., Kohno C., Nishimoto A., Sekine H., Fukai F., Okano T. Cell sheet engineering: recreating tissues without biodegradable scaffolds. Biomaterials 2005, 26:6415-6422.
102. Okano T., Yamada N., Sakai H., Sakurai Y. A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly(N-isopropylacrylamide). J. Biomed. Mater. Res. 1993, 27:1243-1251.
103. Asakawa N., Shimizu T., Tsuda Y., Sekiya S., Sasagawa T., Yamato M., Fukai F., Okano T. Pre-vascularization of in vitro three-dimensional tissues created by cell sheet engineering. Biomaterials 2010, 31:3903-3909.
104. Kim K., Ohashi K., Utoh R., Kano K., Okano T. Preserved liver-specific functions of hepatocytes in 3D co-culture with endothelial cell sheets. Biomaterials 2012, 33:1406-1413.
105. Yang G.P., Soetikno R.M. Treatment of oesophageal ulcerations using endoscopic transplantation of tissue-engineered autologous oral mucosal epithelial cell sheets in a canine model. Gut 2007, 56:313-314.
106. Akimoto J., Takagi S., Nakayama M., Arauchi A., Yamato M., Okano T. Transplantation of cancerous cell sheets effectively generates tumour-bearing model mice. J. Tissue Eng. Regen. Med. 2013, (Epub ahead of print). 10.1002/term.1850.
107. Iwata T., Yamato M., Tsuchioka H., Takagi R., Mukobata S., Washio K., Okano T., Ishikawa I. Periodontal regeneration with multi-layered periodontal ligament-derived cell sheets in a canine model. Biomaterials 2009, 30:2716-2723.
108. Tsumanuma Y., Iwata T., Washio K., Yoshida T., Yamada A., Takagi R., Ohno T., Lin K., Yamato M., Ishikawa I., Okano T., Izumi Y. Comparison of different tissue-derived stem cell sheets for periodontal regeneration in a canine 1-wall defect model. Biomaterials 2011, 32:5819-5825.
109. Costa P.F., Vaquette C., Zhang Q., Reis R.L., Ivanovski S., Hutmacher D.W. Advanced tissue engineering scaffold design for regeneration of the complex hierarchical periodontal structure. J. Clin. Periodontol. 2014, 41:283-294.
110. Sieh S., Lubik A.A., Clements J.A., Nelson C.C., Hutmacher D.W. Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis 2010, 6:181-188.
111. Isenberg B.C., Tsuda Y., Williams C., Shimizu T., Yamato M., Okano T., Wong J.Y. A thermoresponsive, microtextured substrate for cell sheet engineering with defined structural organization. Biomaterials 2008, 29:2565-2572.
112. Yang J., Yamato M., Shimizu T., Sekine H., Ohashi K., Kanzaki M., Ohki T., Nishida K., Okano T. Reconstruction of functional tissues with cell sheet engineering. Biomaterials 2007, 28:5033-5043.
113. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
114. Frieboes H.B., Zheng X., Sun C.H., Tromberg B., Gatenby R., Cristini V. An integrated computational/experimental model of tumor invasion. Cancer Res. 2006, 66:1597-1604.
115. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
116. Thoma C.R., Zimmermann M., Agarkova I., Kelm J.M., Krek W. 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv. Drug Deliv. Rev. 2014, 69-70C:29-41.
117. Dolznig H., Walzl A., Kramer N., Rosner M., Garin-Chesa P., Hengstschlager M. Organotypic spheroid cultures to study tumor-stroma interaction during cancer development. Drug Discov Today Dis Models 2011, 8:113-119.
118. Blangy A., Lane H.A., d'Herin P., Harper M., Kress M., Nigg E.A. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995, 83:1159-1169.
119. Thoma C.R., Stroebel S., Rosch N., Calpe B., Krek W., Kelm J.M. A high-throughput-compatible 3D microtissue co-culture system for phenotypic RNAi screening applications. J. Biomol. Screen. 2013, 18:1330-1337.
120. Hoffmann T.K., Schirlau K., Sonkoly E., Brandau S., Lang S., Pivarcsi A., Balz V., Muller A., Homey B., Boelke E., Reichert T., Friebe-Hoffmann U., Greve J., Schuler P., Scheckenbach K., Schipper J., Bas M., Whiteside T.L., Bier H. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int. J. Cancer 2009, 124:2589-2596.
121. Graves D.T., Valente A.J. Monocyte chemotactic proteins from human tumor cells. Biochem. Pharmacol. 1991, 41:333-337.
122. Wenzel C., Riefke B., Grundemann S., Krebs A., Christian S., Prinz F., Osterland M., Golfier S., Rase S., Ansari N., Esner M., Bickle M., Pampaloni F., Mattheyer C., Stelzer E.H., Parczyk K., Prechtl S., Steigemann P. 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp. Cell Res. 2014, 323:131-143.
123. Lee J.A., Berg E.L. Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches. J. Biomol. Screen. 2013, 18:1143-1155.
124. Rintoul R.C., Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin. Sci. 2002, 102:417-424.
125. Kenny P.A. Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem. Soc. Trans. 2007, 35:665-668.
126. Lee J.M., Mhawech-Fauceglia P., Lee N., Parsanian L.C., Lin Y.G., Gayther S.A., Lawrenson K. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab. Invest. 2013, 93:528-542.
127. Dolznig H., Rupp C., Puri C., Haslinger C., Schweifer N., Wieser E., Kerjaschki D., Garin-Chesa P. Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction. Am. J. Pathol. 2011, 179:487-501.
128. Lee G.Y., Kenny P.A., Lee E.H., Bissell M.J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 2007, 4:359-365.
129. Yip D., Cho C.H. A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem. Biophys. Res. Commun. 2013, 433:327-332.
130. Pickard A., Cichon A.C., Barry A., Kieran D., Patel D., Hamilton P., Salto-Tellez M., James J., McCance D.J. Inactivation of Rb in stromal fibroblasts promotes epithelial cell invasion. EMBO J. 2012, 31:3092-3103.
131. Timpson P., McGhee E.J., Erami Z., Nobis M., Quinn J.A., Edward M., Anderson K.I. Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context. J. Vis. Exp. 2011, e3089.
132. Weigelt B., Ghajar C.M., Bissell M.J. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv. Drug Deliv. Rev. 2014, 69-70C:42-51.
133. Tiago M., de Oliveira E.M., Brohem C.A., Pennacchi P.C., Paes R.D., Haga R.B., Campa A., Barros S.B., Smalley K.S., Maria-Engler S.S. Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin. Tissue Eng. Part A 2014, 20:2412-2421.
134. Maas-Szabowski N., Szabowski A., Stark H.J., Andrecht S., Kolbus A., Schorpp-Kistner M., Angel P., Fusenig N.E. Organotypic cocultures with genetically modified mouse fibroblasts as a tool to dissect molecular mechanisms regulating keratinocyte growth and differentiation. J. Invest. Dermatol. 2001, 116:816-820.
135. Froeling F.E., Mirza T.A., Feakins R.M., Seedhar A., Elia G., Hart I.R., Kocher H.M. Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am. J. Pathol. 2009, 175:636-648.
136. van Zijl F., Mair M., Csiszar A., Schneller D., Zulehner G., Huber H., Eferl R., Beug H., Dolznig H., Mikulits W. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009, 28:4022-4033.
137. Nystrom M.L., Thomas G.J., Stone M., Mackenzie I.C., Hart I.R., Marshall J.F. Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J. Pathol. 2005, 205:468-475.
138. Seano G., Chiaverina G., Gagliardi P.A., di Blasio L., Sessa R., Bussolino F., Primo L. Modeling human tumor angiogenesis in a three-dimensional culture system. Blood 2013, 121:e129-e137.
139. Ghajar C.M., Peinado H., Mori H., Matei I.R., Evason K.J., Brazier H., Almeida D., Koller A., Hajjar K.A., Stainier D.Y., Chen E.I., Lyden D., Bissell M.J. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 2013, 15:807-817.
140. Bechetoille N., Vachon H., Gaydon A., Boher A., Fontaine T., Schaeffer E., Decossas M., Andre-Frei V., Mueller C.G. A new organotypic model containing dermal-type macrophages. Exp. Dermatol. 2011, 20:1035-1037.
141. Linde N., Gutschalk C.M., Hoffmann C., Yilmaz D., Mueller M.M. Integrating macrophages into organotypic co-cultures: a 3D in vitro model to study tumor-associated macrophages. PLoS One 2012, 7:e40058.
142. Mathes S.H., Ruffner H., Graf-Hausner U. The use of skin models in drug development. Adv. Drug Deliv. Rev. 2014, 69-70C:81-102.
143. Ridky T.W., Chow J.M., Wong D.J., Khavari P.A. Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat. Med. 2010, 16:1450-1455.
144. Nobis M., McGhee E.J., Morton J.P., Schwarz J.P., Karim S.A., Quinn J., Edward M., Campbell A.D., McGarry L.C., Evans T.R., Brunton V.G., Frame M.C., Carragher N.O., Wang Y., Sansom O.J., Timpson P., Anderson K.I. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. Cancer Res. 2013, 73:4674-4686.
145. Vorsmann H., Groeber F., Walles H., Busch S., Beissert S., Walczak H., Kulms D. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell DeathDis. 2013, 4:e719.
146. Hutmacher D.W., Loessner D., Rizzi S., Kaplan D.L., Mooney D.J., Clements J.A. Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol. 2010, 28:125-133.
147. Chan H.F., Zhang Y., Ho Y.P., Chiu Y.L., Jung Y., Leong K.W. Rapid formation of multicellular spheroids in double-emulsion droplets with controllable microenvironment. Sci. Rep. 2013, 3:3462.
148. Lim F., Sun A.M. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980, 210:908-910.
149. Papas K.K., Long R.C., Sambanis A., Constantinidis I. Development of a bioartificial pancreas: I. long-term propagation and basal and induced secretion from entrapped betaTC3 cell cultures. Biotechnol. Bioeng. 1999, 66:219-230.
150. Kolambkar Y.M., Boerckel J.D., Dupont K.M., Bajin M., Huebsch N., Mooney D.J., Hutmacher D.W., Guldberg R.E. Spatiotemporal delivery of bone morphogenetic protein enhances functional repair of segmental bone defects. Bone 2011, 49:485-492.
151. Kolambkar Y.M., Dupont K.M., Boerckel J.D., Huebsch N., Mooney D.J., Hutmacher D.W., Guldberg R.E. An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 2011, 32:65-74.
152. Venkatesan J., Bhatnagar I., Manivasagan P., Kang K.H., Kim S.K. Alginate composites for bone tissue engineering: a review. Int. J. Biol. Macromol. 2014, 72C:269-281.
153. Rowley J.A., Madlambayan G., Mooney D.J. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 1999, 20:45-53.
154. Fischbach C., Kong H.J., Hsiong S.X., Evangelista M.B., Yuen W., Mooney D.J. Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:399-404.
155. Lan S.F., Starly B. Alginate based 3D hydrogels as an in vitro co-culture model platform for the toxicity screening of new chemical entities. Toxicol. Appl. Pharmacol. 2011, 256:62-72.
156. Branco da Cunha C., Klumpers D.D., Li W.A., Koshy S.T., Weaver J.C., Chaudhuri O., Granja P.L., Mooney D.J. Influence of the stiffness of three-dimensional alginate/collagen-I interpenetrating networks on fibroblast biology. Biomaterials 2014, 35:8927-8936.
157. Chaudhuri O., Koshy S.T., Branco da Cunha C., Shin J.W., Verbeke C.S., Allison K.H., Mooney D.J. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. Nat. Mater. 2014, 13:970-978.
158. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., Reinhart-King C.A., Margulies S.S., Dembo M., Boettiger D., Hammer D.A., Weaver V.M. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
159. Provenzano P.P., Inman D.R., Eliceiri K.W., Keely P.J. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009, 28:4326-4343.
160. Nguyen-Ngoc K.V., Cheung K.J., Brenot A., Shamir E.R., Gray R.S., Hines W.C., Yaswen P., Werb Z., Ewald A.J. ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2595-E2604.
161. Andersen T., Markussen C., Dornish M., Heier-Baardson H., Melvik J.E., Alsberg E., Christensen B.E. In situ gelation for cell immobilization and culture in alginate foam scaffolds. Tissue Eng. Part A 2014, 20:600-610.
162. Godugu C., Patel A.R., Desai U., Andey T., Sams A., Singh M. AlgiMatrix based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One 2013, 8:e53708.
163. Lee D.W., Choi Y.S., Seo Y.J., Lee M.Y., Jeon S.Y., Ku B., Kim S., Yi S.H., Nam D.H. High-throughput screening (HTS) of anticancer drug efficacy on a micropillar/microwell chip platform. Anal. Chem. 2014, 86:535-542.
164. Kerjaschki D., Bago-Horvath Z., Rudas M., Sexl V., Schneckenleithner C., Wolbank S., Bartel G., Krieger S., Kalt R., Hantusch B., Keller T., Nagy-Bojarszky K., Huttary N., Raab I., Lackner K., Krautgasser K., Schachner H., Kaserer K., Rezar S., Madlener S., Vonach C., Davidovits A., Nosaka H., Hammerle M., Viola K., Dolznig H., Schreiber M., Nader A., Mikulits W., Gnant M., Hirakawa S., Detmar M., Alitalo K., Nijman S., Offner F., Maier T.J., Steinhilber D., Krupitza G. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J. Clin. Invest. 2011, 121:2000-2012.
165. Vonach C., Viola K., Giessrigl B., Huttary N., Raab I., Kalt R., Krieger S., Vo T.P., Madlener S., Bauer S., Marian B., Hammerle M., Kretschy N., Teichmann M., Hantusch B., Stary S., Unger C., Seelinger M., Eger A., Mader R., Jager W., Schmidt W., Grusch M., Dolznig H., Mikulits W., Krupitza G. NF-kappaB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. Br. J. Cancer 2011, 105:263-271.
166. Viola K., Kopf S., Huttary N., Vonach C., Kretschy N., Teichmann M., Giessrigl B., Raab I., Stary S., Krieger S., Keller T., Bauer S., Hantusch B., Szekeres T., de Martin R., Jager W., Mikulits W., Dolznig H., Krupitza G., Grusch M. Bay11-7082 inhibits the disintegration of the lymphendothelial barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion. Br. J. Cancer 2013, 108:564-569.
167. Kretschy N., Teichmann M., Kopf S., Atanasov A.G., Saiko P., Vonach C., Viola K., Giessrigl B., Huttary N., Raab I., Krieger S., Jager W., Szekeres T., Nijman S.M., Mikulits W., Dirsch V.M., Dolznig H., Grusch M., Krupitza G. In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen. Br. J. Cancer 2013, 108:570-578.
168. Teichmann M., Kretschy N., Kopf S., Jarukamjorn K., Atanasov A.G., Viola K., Giessrigl B., Saiko P., Szekeres T., Mikulits W., Dirsch V.M., Huttary N., Krieger S., Jager W., Grusch M., Dolznig H., Krupitza G. Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: drug testing in a 3D model. Arch. Toxicol. 2014, 88:691-699.
169. Kopf S., Viola K., Atanasov A.G., Jarukamjorn K., Rarova L., Kretschy N., Teichmann M., Vonach C., Saiko P., Giessrigl B., Huttary N., Raab I., Krieger S., Schumacher M., Diederich M., Strnad M., de Martin R., Szekeres T., Jager W., Dirsch V.M., Mikulits W., Grusch M., Dolznig H., Krupitza G. In vitro characterisation of the anti-intravasative properties of the marine product heteronemin. Arch. Toxicol. 2013, 87:1851-1861.
170. Viola K., Kopf S., Rarova L., Jarukamjorn K., Kretschy N., Teichmann M., Vonach C., Atanasov A.G., Giessrigl B., Huttary N., Raab I., Krieger S., Strnad M., de Martin R., Saiko P., Szekeres T., Knasmuller S., Dirsch V.M., Jager W., Grusch M., Dolznig H., Mikulits W., Krupitza G. Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. Arch. Toxicol. 2013, 87:1301-1312.
171. Whitesides G.M. The origins and the future of microfluidics. Nature 2006, 442:368-373.
172. Wlodkowic D., Cooper J.M. Tumors on chips: oncology meets microfluidics. Curr. Opin. Chem. Biol. 2010, 14:556-567.
173. Takayama S., Ostuni E., LeDuc P., Naruse K., Ingber D.E., Whitesides G.M. Subcellular positioning of small molecules. Nature 2001, 411:1016.
174. Wong K.H., Chan J.M., Kamm R.D., Tien J. Microfluidic models of vascular functions. Annu. Rev. Biomed. Eng. 2012, 14:205-230.
175. Liu T.C., Wohland T., Watt F., Bettiol A., Udalagama C., Wang L.P. A new technology for revealing the flow profile in integrated lab-on-a-chip. Med. Phys. 2012, 39:5060-5064.
176. Dittrich P.S., Manz A. Lab-on-a-chip: microfluidics in drug discovery. Nat. Rev. Drug Discov. 2006, 5:210-218.
177. Kovarik M.L., Ornoff D.M., Melvin A.T., Dobes N.C., Wang Y., Dickinson A.J., Gach P.C., Shah P.K., Allbritton N.L. Micro total analysis systems: fundamental advances and applications in the laboratory, clinic, and field. Anal. Chem. 2013, 85:451-472.
178. Huh D., Hamilton G.A., Ingber D.E. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011, 21:745-754.
179. Huh D., Matthews B.D., Mammoto A., Montoya-Zavala M., Hsin H.Y., Ingber D.E. Reconstituting organ-level lung functions on a chip. Science 2010, 328:1662-1668.
180. Young E.W. Cells, tissues, and organs on chips: challenges and opportunities for the cancer tumor microenvironment. Integr. Biol. 2013, 5:1096-1109.
181. Jang K.J., Mehr A.P., Hamilton G.A., McPartlin L.A., Chung S., Suh K.Y., Ingber D.E. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr. Biol. 2013, 5:1119-1129.
182. Lee P.J., Hung P.J., Lee L.P. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol. Bioeng. 2007, 97:1340-1346.
183. Esch M.B., Smith A.S., Prot J.M., Oleaga C., Hickman J.J., Shuler M.L. How multi-organ microdevices can help foster drug development. Adv. Drug Deliv. Rev. 2014, 69-70C:158-169.
184. Chaw K.C., Manimaran M., Tay E.H., Swaminathan S. Multi-step microfluidic device for studying cancer metastasis. Lab Chip 2007, 7:1041-1047.
185. Kuo C.T., Chiang C.L., Chang C.H., Liu H.K., Huang G.S., Huang R.Y., Lee H., Huang C.S., Wo A.M. Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics. Biomaterials 2014, 35:1562-1571.
186. Sung J.H., Kam C., Shuler M.L. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 2010, 10:446-455.
187. Wu L.Y., Di Carlo D., Lee L.P. Microfluidic self-assembly of tumor spheroids for anticancer drug discovery. Biomed. Microdevices 2008, 10:197-202.
188. Sung K.E., Yang N., Pehlke C., Keely P.J., Eliceiri K.W., Friedl A., Beebe D.J. Transition to invasion in breast cancer: a microfluidic in vitro model enables examination of spatial and temporal effects. Integr. Biol. 2011, 3:439-450.
189. Ma H., Liu T., Qin J., Lin B. Characterization of the interaction between fibroblasts and tumor cells on a microfluidic co-culture device. Electrophoresis 2010, 31:1599-1605.
190. Mattei F., Schiavoni G., De Ninno A., Lucarini V., Sestili P., Sistigu A., Fragale A., Sanchez M., Spada M., Gerardino A., Belardelli F., Businaro L., Gabriele L. A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. J. Immunotoxicol. 2014, 11:337-346.
191. Zervantonakis I.K., Hughes-Alford S.K., Charest J.L., Condeelis J.S., Gertler F.B., Kamm R.D. Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:13515-13520.
192. Elliott N.T., Yuan F. A microfluidic system for investigation of extravascular transport and cellular uptake of drugs in tumors. Biotechnol. Bioeng. 2012, 109:1326-1335.
193. Sung J.H., Shuler M.L. A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip 2009, 9:1385-1394.
194. Wang L., Liu W., Wang Y., Wang J.C., Tu Q., Liu R., Wang J. Construction of oxygen and chemical concentration gradients in a single microfluidic device for studying tumor cell-drug interactions in a dynamic hypoxia microenvironment. Lab Chip 2013, 13:695-705.
195. Kim C., Bang J.H., Kim Y.E., Lee S.H., Kang J.Y. On-chip anticancer drug test of regular tumor spheroids formed in microwells by a distributive microchannel network. Lab Chip 2012, 12:4135-4142.
196. Gleghorn J.P., Pratt E.D., Denning D., Liu H., Bander N.H., Tagawa S.T., Nanus D.M., Giannakakou P.A., Kirby B.J. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010, 10:27-29.
197. Kirby B.J., Jodari M., Loftus M.S., Gakhar G., Pratt E.D., Chanel-Vos C., Gleghorn J.P., Santana S.M., Liu H., Smith J.P., Navarro V.N., Tagawa S.T., Bander N.H., Nanus D.M., Giannakakou P. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One 2012, 7:e35976.
198. Barker N., van Es J.H., Kuipers J., Kujala P., van den Born M., Cozijnsen M., Haegebarth A., Korving J., Begthel H., Peters P.J., Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-1007.
199. Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., van Es J.H., Abo A., Kujala P., Peters P.J., Clevers H. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459:262-265.
200. Sato T., Stange D.E., Ferrante M., Vries R.G., Van Es J.H., Van den Brink S., Van Houdt W.J., Pronk A., Van Gorp J., Siersema P.D., Clevers H. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011, 141:1762-1772.
201. Hirokawa Y., Yip K.H., Tan C.W., Burgess A.W. Colonic myofibroblast cell line stimulates colonoid formation. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 306:G547-G556.
202. Prasetyanti P.R., Zimberlin C.D., Bots M., Vermeulen L., Melo Fde S., Medema J.P. Regulation of stem cell self-renewal and differentiation by Wnt and Notch are conserved throughout the adenoma-carcinoma sequence in the colon. Mol. Cancer 2013, 12:126.
203. Greggio C., De Franceschi F., Figueiredo-Larsen M., Gobaa S., Ranga A., Semb H., Lutolf M., Grapin-Botton A. Artificial three-dimensional niches deconstruct pancreas development in vitro. Development 2013, 140:4452-4462.
204. Astashkina A.I., Mann B.K., Prestwich G.D., Grainger D.W. A 3-D organoid kidney culture model engineered for high-throughput nephrotoxicity assays. Biomaterials 2012, 33:4700-4711.
205. Barker N., Huch M., Kujala P., van de Wetering M., Snippert H.J., van Es J.H., Sato T., Stange D.E., Begthel H., van den Born M., Danenberg E., van den Brink S., Korving J., Abo A., Peters P.J., Wright N., Poulsom R., Clevers H. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010, 6:25-36.
206. Huch M., Dorrell C., Boj S.F., van Es J.H., Li V.S., van de Wetering M., Sato T., Hamer K., Sasaki N., Finegold M.J., Haft A., Vries R.G., Grompe M., Clevers H. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 2013, 494:247-250.
207. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-1270.
208. Lukacs R.U., Goldstein A.S., Lawson D.A., Cheng D., Witte O.N. Isolation, cultivation and characterization of adult murine prostate stem cells. Nat. Protoc. 2010, 5:702-713.
209. Rock J.R., Onaitis M.W., Rawlins E.L., Lu Y., Clark C.P., Xue Y., Randell S.H., Hogan B.L. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12771-12775.
210. Wang N., Zhang H., Zhang B.Q., Liu W., Zhang Z., Qiao M., Zhang H., Deng F., Wu N., Chen X., Wen S., Zhang J., Liao Z., Zhang Q., Yan Z., Yin L., Ye J., Deng Y., Luu H.H., Haydon R.C., Liang H., He T.C. Adenovirus-mediated efficient gene transfer into cultured three-dimensional organoids. PLoS One 2014, 9:e93608.
211. Onuma K., Ochiai M., Orihashi K., Takahashi M., Imai T., Nakagama H., Hippo Y. Genetic reconstitution of tumorigenesis in primary intestinal cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:11127-11132.
212. Ranga A., Gjorevski N., Lutolf M.P. Drug discovery through stem cell-based organoid models. Adv. Drug Deliv. Rev. 2014, 69-70C:19-28.
213. Sachs N., Clevers H. Organoid cultures for the analysis of cancer phenotypes. Curr. Opin. Genet. Dev. 2014, 24:68-73.
214. Gahwiler B.H. Organotypic cultures of neural tissue. Trends Neurosci. 1988, 11:484-489.
215. Vaira V., Fedele G., Pyne S., Fasoli E., Zadra G., Bailey D., Snyder E., Faversani A., Coggi G., Flavin R., Bosari S., Loda M. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8352-8356.
216. van der Kuip H., Murdter T.E., Sonnenberg M., McClellan M., Gutzeit S., Gerteis A., Simon W., Fritz P., Aulitzky W.E. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 2006, 6:86.
217. Grosso S.H., Katayama M.L., Roela R.A., Nonogaki S., Soares F.A., Brentani H., Lima L., Folgueira M.A., Waitzberg A.F., Pasini F.S., Goes J.C., Brentani M.M. Breast cancer tissue slices as a model for evaluation of response to rapamycin. Cell Tissue Res. 2013, 352:671-684.
218. Cheung K.J., Gabrielson E., Werb Z., Ewald A.J. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 2013, 155:1639-1651.
219. Zhang C., Zhao Z., Abdul Rahim N.A., van Noort D., Yu H. Towards a human-on-chip: culturing multiple cell types on a chip with compartmentalized microenvironments. Lab Chip 2009, 9:3185-3192.
220. Barnes D., Sato G. Serum-free cell culture: a unifying approach. Cell 1980, 22:649-655.
221. Collodi P., Rawson C., Barnes D. Serum-free culture of carcinoma cell lines. Cytotechnology 1991, 5:31-46.
222. Gottipamula S., Muttigi M.S., Kolkundkar U., Seetharam R.N. Serum-free media for the production of human mesenchymal stromal cells: a review. Cell Prolif. 2013, 46:608-627.
223. Davis H., Gonzalez M., Bhargava N., Stancescu M., Hickman J.J., Lambert S. Rat cortical oligodendrocyte-embryonic motoneuron co-culture: an axon-oligodendrocyte interaction model. J. Biomater. Tissue Eng. 2012, 2:206-214.
224. Guo X., Gonzalez M., Stancescu M., Vandenburgh H.H., Hickman J.J. Neuromuscular junction formation between human stem cell-derived motoneurons and human skeletal muscle in a defined system. Biomaterials 2011, 32:9602-9611.
225. Ramirez C.N., Antczak C., Djaballah H. Cell viability assessment: toward content-rich platforms. Expert Opin. Drug Discov. 2010, 5:223-233.
226. Ng K.W., Leong D.T., Hutmacher D.W. The challenge to measure cell proliferation in two and three dimensions. Tissue Eng. 2005, 11:182-191.
227. Quent V.M., Loessner D., Friis T., Reichert J.C., Hutmacher D.W. Discrepancies between metabolic activity and DNA content as tool to assess cell proliferation in cancer research. J. Cell. Mol. Med. 2010, 14:1003-1013.
228. Walzl A., Unger C., Kramer N., Unterleuthner D., Scherzer M., Hengstschlager M., Schwanzer-Pfeiffer D., Dolznig H. The Resazurin reduction assay can distinguish cytotoxic from cytostatic compounds in spheroid screening assays. J. Biomol. Screen. 2014, 19.
229. McMillin D.W., Delmore J., Weisberg E., Negri J.M., Geer D.C., Klippel S., Mitsiades N., Schlossman R.L., Munshi N.C., Kung A.L., Griffin J.D., Richardson P.G., Anderson K.C., Mitsiades C.S. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 2010, 16:483-489.
230. Maguire C.A., Bovenberg M.S., Crommentuijn M.H., Niers J.M., Kerami M., Teng J., Sena-Esteves M., Badr C.E., Tannous B.A. Triple bioluminescence imaging for in vivo monitoring of cellular processes, Molecular therapy. Nucleic Acids 2013, 2:e99.
231. Ramanathan M., Hasko G., Leibovich S.J. Analysis of signal transduction pathways in macrophages using expression vectors with CMV promoters: a cautionary tale. Inflammation 2005, 29:94-102.
232. Peterson J.K., Houghton P.J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 2004, 40:837-844.
233. Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2003, 2:S134-S139.
234. Lancaster M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Homfray T., Penninger J.M., Jackson A.P., Knoblich J.A. Cerebral organoids model human brain development and microcephaly. Nature 2013, 501:373-379.
235. Jakab K., Damon B., Neagu A., Kachurin A., Forgacs G. Three-dimensional tissue constructs built by bioprinting. Biorheology 2006, 43:509-513.
236. Snyder J.E., Hamid Q., Wang C., Chang R., Emami K., Wu H., Sun W. Bioprinting cell-laden matrigel for radioprotection study of liver by pro-drug conversion in a dual-tissue microfluidic chip. Biofabrication 2011, 3:034112.
237. Huang T.Q., Qu X., Liu J., Chen S. 3D printing of biomimetic microstructures for cancer cell migration. Biomed. Microdevices 2014, 16:127-132.
238. Kolesky D.B., Truby R.L., Gladman A.S., Busbee T.A., Homan K.A., Lewis J.A. 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs. Adv. Mater. 2014, 26:3124-3130.
239. Zhao Y., Yao R., Ouyang L., Ding H., Zhang T., Zhang K., Cheng S., Sun W. Three-dimensional printing of HeLa cells for cervical tumor model in vitro. Biofabrication 2014, 6:035001.
240. Miller J.S., Stevens K.R., Yang M.T., Baker B.M., Nguyen D.H., Cohen D.M., Toro E., Chen A.A., Galie P.A., Yu X., Chaturvedi R., Bhatia S.N., Chen C.S. Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat. Mater. 2012, 11:768-774.
241. Whitesides G.M., Ostuni E., Takayama S., Jiang X., Ingber D.E. Soft lithography in biology and biochemistry. Annu. Rev. Biomed. Eng. 2001, 3:335-373.
242. Chrobak K.M., Potter D.R., Tien J. Formation of perfused, functional microvascular tubes in vitro. Microvasc. Res. 2006, 71:185-196.
243. Shin Y., Han S., Jeon J.S., Yamamoto K., Zervantonakis I.K., Sudo R., Kamm R.D., Chung S. Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels. Nat. Protoc. 2012, 7:1247-1259.
244. Kim S., Lee H., Chung M., Jeon N.L. Engineering of functional, perfusable 3D microvascular networks on a chip. Lab Chip 2013, 13:1489-1500.
245. Seo B.R., Delnero P., Fischbach C. In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer. Adv. Drug Deliv. Rev. 2014, 69-70C:205-216.